BACKGROUND: Little information about the incidence of retropharyngeal adenopathy and its impact on prognosis has been published. METHODS: For 774 patients with squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx, or supraglottic larynx, pretreatment CT and, in selected cases, MRI scans were reviewed to determine the presence of retropharyngeal adenopathy. Results were analyzed in 619 patients treated with curative intent to determine the prognostic impact of retropharyngeal adenopathy. RESULTS: The highest incidence of retropharyngeal adenopathy was seen in patients with nasopharyngeal (74%) and pharyngeal wall (19%) cancers. The number of cervical nodal groups involved was the most significant factor (p < .0001) relating to the incidence of retropharyngeal adenopathy. The rates of neck relapse (40% at 5 years) and distant metastasis were significantly higher in patients with retropharyngeal adenopathy, and the rates of 5-year relapse-free survival and absolute survival were significantly lower. CONCLUSIONS: Retropharyngeal adenopathy is a strong predictor of poor prognosis, particularly for patients with advanced neck disease.
BACKGROUND: Little information about the incidence of retropharyngeal adenopathy and its impact on prognosis has been published. METHODS: For 774 patients with squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx, or supraglottic larynx, pretreatment CT and, in selected cases, MRI scans were reviewed to determine the presence of retropharyngeal adenopathy. Results were analyzed in 619 patients treated with curative intent to determine the prognostic impact of retropharyngeal adenopathy. RESULTS: The highest incidence of retropharyngeal adenopathy was seen in patients with nasopharyngeal (74%) and pharyngeal wall (19%) cancers. The number of cervical nodal groups involved was the most significant factor (p < .0001) relating to the incidence of retropharyngeal adenopathy. The rates of neck relapse (40% at 5 years) and distant metastasis were significantly higher in patients with retropharyngeal adenopathy, and the rates of 5-year relapse-free survival and absolute survival were significantly lower. CONCLUSIONS:Retropharyngeal adenopathy is a strong predictor of poor prognosis, particularly for patients with advanced neck disease.
Authors: L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa Journal: Acta Otorhinolaryngol Ital Date: 2005-02 Impact factor: 2.124
Authors: Matthew E Spector; Steven B Chinn; Emily Bellile; K Kelly Gallagher; Stephen Y Kang; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; Thomas E Carey; Francis P Worden; Avraham Eisbruch; Mohannad Ibrahim; Douglas B Chepeha Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-04 Impact factor: 6.223
Authors: Stuart E Samuels; Jeffrey Vainshtein; Matthew E Spector; Mohannad Ibrahim; Jonathan B McHugh; Yebin Tao; Matthew Schipper; Francis Worden; Avraham Eisbruch Journal: Radiother Oncol Date: 2015-06-17 Impact factor: 6.280
Authors: G Brandon Gunn; J Matthew Debnam; Clifton D Fuller; William H Morrison; Steven J Frank; Beth M Beadle; Erich M Sturgis; Bonnie S Glisson; Jack Phan; David I Rosenthal; Adam S Garden Journal: Cancer Date: 2013-06-03 Impact factor: 6.860
Authors: Nam P Nguyen; Jacqueline Vock; Vincent Vinh-Hung; Fabio Almeida; Lars Ewell; Michael Betz; Siyoung Jang; Richard A Vo; Suresh Dutta; Juan Godinez; Ulf Karlsson; Alexander Chi Journal: BMC Cancer Date: 2012-06-18 Impact factor: 4.430
Authors: Stuart E Samuels; Avraham Eisbruch; Jonathan J Beitler; June Corry; Carol R Bradford; Nabil F Saba; Michiel W M van den Brekel; Robert Smee; Primož Strojan; Carlos Suárez; William M Mendenhall; Robert P Takes; Juan P Rodrigo; Missak Haigentz; Alexander D Rapidis; Alessandra Rinaldo; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2015-10-13 Impact factor: 3.236
Authors: Waleed F Mourad; Dukagjin M Blakaj; Rafi Kabarriti; Rebekah Young; Rania A Shourbaji; Jonathan Glanzman; Shyamal Patel; Ravindra Yaparpalvi; Shalom Kalnicki; Madhur K Garg Journal: Case Rep Oncol Med Date: 2013-06-13